326 related articles for article (PubMed ID: 29121178)
1. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.
Beswick L; Rosella O; Rosella G; Headon B; Sparrow MP; Gibson PR; van Langenberg DR
J Crohns Colitis; 2018 Feb; 12(3):289-297. PubMed ID: 29121178
[TBL] [Abstract][Full Text] [Related]
2. CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis.
Gibson DJ; Hartery K; Doherty J; Nolan J; Keegan D; Byrne K; Martin ST; Buckley M; Sheridan J; Horgan G; Mulcahy HE; Cullen G; Doherty GA
J Clin Gastroenterol; 2018 Jul; 52(6):e48-e52. PubMed ID: 28737646
[TBL] [Abstract][Full Text] [Related]
3. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.
Ho GT; Lee HM; Brydon G; Ting T; Hare N; Drummond H; Shand AG; Bartolo DC; Wilson RG; Dunlop MG; Arnott ID; Satsangi J
Am J Gastroenterol; 2009 Mar; 104(3):673-8. PubMed ID: 19262524
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
6. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.
Whaley KG; Xiong Y; Karns R; Hyams JS; Kugathasan S; Boyle BM; Walters TD; Kelsen J; LeLeiko N; Shapiro J; Waddell A; Fox S; Bezold R; Bruns S; Widing R; Haberman Y; Collins MH; Mizuno T; Minar P; D'Haens GR; Denson LA; Vinks AA; Rosen MJ
Clin Gastroenterol Hepatol; 2023 May; 21(5):1338-1347. PubMed ID: 36031093
[TBL] [Abstract][Full Text] [Related]
7. Predicting response after infliximab salvage in acute severe ulcerative colitis.
Choy MC; Seah D; Gorelik A; An YK; Chen CY; Macrae FA; Sparrow MP; Connell WR; Moore GT; Radford-Smith G; Van Langenberg DR; De Cruz P
J Gastroenterol Hepatol; 2018 Jul; 33(7):1347-1352. PubMed ID: 29266456
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
9. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab.
D'Arcangelo G; Oliva S; Dilillo A; Viola F; Civitelli F; Isoldi S; Cucchiara S; Aloi M
J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):841-846. PubMed ID: 30633110
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis.
Sahu P; Jain S; Kedia S; Vuyyuru SK; Sahni P; Sharma R; Panwar R; Das P; Gupta V; Makharia G; Travis S; Ahuja V
Indian J Gastroenterol; 2022 Jun; 41(3):273-283. PubMed ID: 35474175
[TBL] [Abstract][Full Text] [Related]
12. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.
Chao CY; Al Khoury A; Aruljothy A; Restellini S; Wyse J; Afif W; Bitton A; Lakatos PL; Bessissow T
Dig Dis Sci; 2019 Feb; 64(2):518-523. PubMed ID: 30446928
[TBL] [Abstract][Full Text] [Related]
14. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.
Ordás I; Domènech E; Mañosa M; García-Sánchez V; Iglesias-Flores E; Peñalva M; Cañas-Ventura A; Merino O; Fernández-Bañares F; Gomollón F; Vera M; Gutiérrez A; Garcia-Planella E; Chaparro M; Aguas M; Gento E; Muñoz F; Aguirresarobe M; Muñoz C; Fernández L; Calvet X; Jiménez CE; Montoro MA; Mir A; De Castro ML; García-Sepulcre MF; Bermejo F; Panés J; Esteve M
Am J Gastroenterol; 2017 Nov; 112(11):1709-1718. PubMed ID: 28675163
[TBL] [Abstract][Full Text] [Related]
17. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
[TBL] [Abstract][Full Text] [Related]
19. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
Battat R; Hemperly A; Truong S; Whitmire N; Boland BS; Dulai PS; Holmer AK; Nguyen NH; Singh S; Vande Casteele N; Sandborn WJ
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):511-518.e6. PubMed ID: 32348905
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
